| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Folh1 |
| Uniprot No | Q04609 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 44-750aa |
| 氨基酸序列 | KSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLA KQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSL FEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMK INCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYP DGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIP VHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVK MHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAA VVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQ ERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSL YESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWET NKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVL PFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIA SKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYA PSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAA ETLSEVA |
| 预测分子量 | 80 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3-4条关于 **Folh1(PSMA)重组蛋白** 的参考文献及摘要概括：
1. **文献名称**：*"Cloning and Expression of Human Prostate-Specific Membrane Antigen (PSMA) in Escherichia coli"*
**作者**：Troyer JK, Beckett ML, Wright GL
**摘要**：该研究报道了人源Folh1(PSMA)基因的克隆及在大肠杆菌中的重组表达，分析了重组蛋白的酶活性和前列腺癌细胞特异性结合能力，为后续诊断应用奠定基础。
2. **文献名称**：*"Structural Basis of Substrate Specificity in Folate Hydrolase (PSMA) Revealed by X-ray Crystallography"*
**作者**：Pang X, Zhou HX, et al.
**摘要**：通过X射线晶体学解析了重组PSMA蛋白的三维结构，揭示了其底物结合域的构象特征，为设计靶向PSMA的小分子抑制剂提供结构依据。
3. **文献名称**：*"Recombinant PSMA-Targeting Antibodies for Prostate Cancer Imaging and Therapy"*
**作者**：Ghosh A, Heston WD
**摘要**：研究利用重组PSMA蛋白开发了高亲和力单克隆抗体，验证其在体外和动物模型中靶向肿瘤细胞的潜力，推动PSMA抗体-药物偶联物(ADC)的临床转化。
4. **文献名称**：*"Development of a PSMA-Specific Nanobody Using Phage Display Technology"*
**作者**：Wang Y, Li Z, et al.
**摘要**：通过噬菌体展示技术筛选出针对重组PSMA的纳米抗体，并证明其在体外检测和体内分子成像中的应用前景，为开发低免疫原性诊断工具提供新策略。
---
**注**：上述文献为示例性质，具体内容建议通过PubMed或Google Scholar以“Folh1 recombinant protein”或“PSMA recombinant”为关键词检索最新研究。
Folh1. also known as folate hydrolase 1 or prostate-specific membrane antigen (PSMA), is a transmembrane glycoprotein with multiple enzymatic functions, primarily acting as a glutamate carboxypeptidase. It plays a key role in folate metabolism by hydrolyzing dietary polyglutamated folates into monoglutamates for cellular uptake. Additionally, Folh1 is involved in neuropeptide processing and interacts with neurotransmitters like N-acetylaspartylglutamate (NAAG). Its expression is notably elevated in prostate cancer cells, making it a widely studied biomarker and therapeutic target for prostate cancer diagnostics and targeted therapies.
Recombinant Folh1 protein is engineered through genetic cloning and expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional protein for research and clinical applications. This engineered protein retains enzymatic activity and structural epitopes, enabling its use in drug discovery, antibody development, and diagnostic assays. For instance, it serves as a critical tool in validating PSMA-targeted therapies, including radioligand therapies (e.g., Lu-PSMA-617) and CAR-T cell immunotherapies. Researchers also employ recombinant Folh1 to study its biochemical properties, substrate specificity, and inhibition mechanisms, aiding the design of small-molecule inhibitors or imaging probes.
Beyond oncology, Folh1's role in neurological disorders and inflammatory conditions has spurred interest in its recombinant form for broader biomedical studies. Its dual function in folate processing and neurosignaling highlights its therapeutic potential across diverse pathologies. Standardized recombinant Folh1 production ensures consistency in preclinical studies, accelerating translational research while minimizing batch-to-batch variability.
×
